Investigators conducted this cross-sectional secondary analysis using baseline data from a phase 3 randomized controlled trial to explore associations between fear of cancer recurrence and coping ...

The odds of human papillomavirus (HPV)-related cancers are increased among people with HIV (PWH) and solid organ transplant recipients (SOTRs), according to a study published online June 30 in JAMA ...

In this systematic review, researchers aimed to analyze the uptake of breast cancer risk management strategies, including prophylactic mastectomy, intensive surveillance, or no active strategy, in ...

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

Investigators compared the safety and efficacy of polatuzumab vedotin with or without rituximab, gemcitabine, and oxaliplatin in first line for patients with relapsed/refractory diffuse large B-cell ...

Rates of prostate cancer screening shared decision-making (SDM) are very low in family medicine practices, according to a study published in the June issue of the Southern Medical Journal. Nicholas ...

In this analysis, researchers examined long-term outcomes for EWS survivors based on chemotherapy regimen, as well as compared to siblings and the general population.

In this long-term follow-up to the phase 2 ARTO trial, researchers analyzed survival outcomes in patients with CRPC treated with metastasis-directed therapy.

ASCO's 2026 annual conference in Chicago featured cutting-edge research on treatment strategies for sarcomas such as GIST and ...

In this phase 3 trial, researchers aimed to characterize the clinical characteristics, treatment approaches, and outcomes of patients with metastatic non-rhabdomyosarcoma soft tissue sarcoma and to ...

More adverse events of grade 3 or higher reported for participants receiving pembrolizumab-belzutifan than pembrolizumab-placebo ...

Investigators in this retrospective cohort study sought to determine long-term outcomes for patients with platinum-sensitive recurrent ovarian cancer who have exceptional response to PARP inhibitors.